Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected]
Non-small cell lung cancer (NSCLC) is the most common cancer and the leading cause of death from cancer worldwide. Antiangiogenic strategies directed towards tumor stroma are becoming gold standard in NSCLC treatment and researchers have been searching for biomarkers to identify patients for whom th...
Gespeichert in:
| Veröffentlicht in: | PloS one 2014-02, Vol.9 (2), p.e90009-e90009 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e90009 |
|---|---|
| container_issue | 2 |
| container_start_page | e90009 |
| container_title | PloS one |
| container_volume | 9 |
| creator | Coelho, Ana L Araújo, António Gomes, Mónica Catarino, Raquel Marques, Agostinho Medeiros, Rui |
| description | Non-small cell lung cancer (NSCLC) is the most common cancer and the leading cause of death from cancer worldwide. Antiangiogenic strategies directed towards tumor stroma are becoming gold standard in NSCLC treatment and researchers have been searching for biomarkers to identify patients for whom therapy with antiangiogenic inhibitors may be most beneficial and the importance of these as prognostic factors in NSCLC. The purpose of this study was to evaluate the prognostic value of circulating Ang-2 mRNA levels prior to treatment in NSCLC patients. The mRNA levels were determined by quantitative real-time PCR in the peripheral blood of 92 NSCLC patients. Our results demonstrate that patients with high circulating Ang-2 mRNA levels have diminished overall survival when compared to those with low mRNA levels (20.3 months vs 34.3 months, respectively; Log Rank Test, p = 0.016), when considering all NSCLC stages and this difference is even bigger when considering only patients with stage IV (15.9 months vs 31.3 months, respectively; Log Rank Test, p = 0.036). Moreover, circulating Ang-2 mRNA levels independently determine overall survival, and the concordance (c) index analysis showed that the definition of a nomogram that contains information regarding tumor stage, patients' smoking status and circulating Ang-2 mRNA levels present an increased capacity to predict overall survival in NSCLC patients (c-index 0.798). These results suggest that this nomogram could serve as a unique and practical tool to determine prognosis in NSCLC, not relying on the availability of adequate surgical or biopsy specimens of NSCLC. Attending to our results, the circulating Ang-2 mRNA levels should also be included in the design of preclinical studies and clinical trials involving antiangiogenic drugs targeting Ang-2, to guide adequate patient stratification and dose selection and increasing the likelihood of benefit to a level that is acceptable to patients and clinicians. |
| doi_str_mv | 10.1371/journal.pone.0090009 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1503272088</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A478787956</galeid><doaj_id>oai_doaj_org_article_f4bc05cdbb10491bb67f27f480e0b850</doaj_id><sourcerecordid>A478787956</sourcerecordid><originalsourceid>FETCH-LOGICAL-c692t-b99f01b83fcf8da04b87c70bd21b1a2e6fac4d978bd1e41cb89e06cb5dc64d113</originalsourceid><addsrcrecordid>eNqNk1trFDEUxwdRbF39BqIBQfRh12SumT4Iy-JlYWmhVV9EQi4ns1OzkzXJ1PrtzXSnZVf6ICEkJL_zPzkn5yTJc4JnJKvIu0vbu46b2dZ2MMO4xnE-SI5JnaXTMsXZw739UfLE-0uMi4yW5ePkKM0LWhFaHCfrRetkb3houwbNu2aaos356RzB9daB963tkIErMP4EGWt_DhRfA1coWMRRB7_R1tmmsz60Emkug3VIx3l6sVgt0HdpnQMZQP14mjzS3Hh4Nq6T5OvHD18Wn6ers0_LxXw1lWWdhqmoa42JoJmWmiqOc0ErWWGhUiIIT6GMPnJVV1QoAjmRgtaASykKJctcEZJNkpc73a2xno1J8owUOEurFFMaieWOUJZfsq1rN9z9YZa37ObAuoZxF8MxwHQuJC6kEoLgvCZClJVOK51TDFjQKDlJ3o_eerEBJaELjpsD0cObrl2zxl6xrM5oQYfnvhkFnP3Vgw9s03oJxvAObH_z7pyU8cPLiL76B70_upFqeAyg7bSNfuUgyuZ5ReOoi0Frdg8Vh4JNK2NF6TaeHxi8PTCITIDr0PDee7a8OP9_9uzbIft6j42VZcLaW9OHWHn-EMx3oHTWewf6LskEs6EhbrPBhoZgY0NEsxf7H3RndNsB2V-FMQYi</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1503272088</pqid></control><display><type>article</type><title>Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected]</title><source>MEDLINE</source><source>TestCollectionTL3OpenAccess</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Free Full-Text Journals in Chemistry</source><source>Public Library of Science (PLoS)</source><creator>Coelho, Ana L ; Araújo, António ; Gomes, Mónica ; Catarino, Raquel ; Marques, Agostinho ; Medeiros, Rui</creator><contributor>Lo, Anthony W. I.</contributor><creatorcontrib>Coelho, Ana L ; Araújo, António ; Gomes, Mónica ; Catarino, Raquel ; Marques, Agostinho ; Medeiros, Rui ; Lo, Anthony W. I.</creatorcontrib><description>Non-small cell lung cancer (NSCLC) is the most common cancer and the leading cause of death from cancer worldwide. Antiangiogenic strategies directed towards tumor stroma are becoming gold standard in NSCLC treatment and researchers have been searching for biomarkers to identify patients for whom therapy with antiangiogenic inhibitors may be most beneficial and the importance of these as prognostic factors in NSCLC. The purpose of this study was to evaluate the prognostic value of circulating Ang-2 mRNA levels prior to treatment in NSCLC patients. The mRNA levels were determined by quantitative real-time PCR in the peripheral blood of 92 NSCLC patients. Our results demonstrate that patients with high circulating Ang-2 mRNA levels have diminished overall survival when compared to those with low mRNA levels (20.3 months vs 34.3 months, respectively; Log Rank Test, p = 0.016), when considering all NSCLC stages and this difference is even bigger when considering only patients with stage IV (15.9 months vs 31.3 months, respectively; Log Rank Test, p = 0.036). Moreover, circulating Ang-2 mRNA levels independently determine overall survival, and the concordance (c) index analysis showed that the definition of a nomogram that contains information regarding tumor stage, patients' smoking status and circulating Ang-2 mRNA levels present an increased capacity to predict overall survival in NSCLC patients (c-index 0.798). These results suggest that this nomogram could serve as a unique and practical tool to determine prognosis in NSCLC, not relying on the availability of adequate surgical or biopsy specimens of NSCLC. Attending to our results, the circulating Ang-2 mRNA levels should also be included in the design of preclinical studies and clinical trials involving antiangiogenic drugs targeting Ang-2, to guide adequate patient stratification and dose selection and increasing the likelihood of benefit to a level that is acceptable to patients and clinicians.</description><identifier>ISSN: 1932-6203</identifier><identifier>EISSN: 1932-6203</identifier><identifier>DOI: 10.1371/journal.pone.0090009</identifier><identifier>PMID: 24587185</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Aged ; Analysis ; Angiogenesis ; Angiopoietin-2 - blood ; Angiopoietin-2 - genetics ; Antiangiogenic agents ; Antiangiogenics ; Biomarkers ; Biomarkers, Tumor - blood ; Biomarkers, Tumor - genetics ; Biopsy ; Cancer ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - blood ; Carcinoma, Non-Small-Cell Lung - diagnosis ; Carcinoma, Non-Small-Cell Lung - genetics ; Carcinoma, Non-Small-Cell Lung - mortality ; Care and treatment ; Chemotherapy ; Clinical trials ; Drug delivery ; Drug development ; Drugs ; Female ; Gene Expression ; Health aspects ; Humans ; Kinases ; Lung cancer ; Lung diseases ; Lung Neoplasms - blood ; Lung Neoplasms - diagnosis ; Lung Neoplasms - genetics ; Lung Neoplasms - mortality ; Male ; Medical prognosis ; Medical research ; Medicine ; Messenger RNA ; Metastasis ; Middle Aged ; Neoplasm Staging ; Nomograms ; Non-small cell lung cancer ; Non-small cell lung carcinoma ; Oncology ; Patients ; Peripheral blood ; Permeability ; Predictive Value of Tests ; Prognosis ; RNA, Messenger - blood ; RNA, Messenger - genetics ; Smoking ; Stroma ; Surgery ; Surgical instruments ; Survival ; Survival Analysis ; Tumors ; Vascular endothelial growth factor</subject><ispartof>PloS one, 2014-02, Vol.9 (2), p.e90009-e90009</ispartof><rights>COPYRIGHT 2014 Public Library of Science</rights><rights>2014 Coelho et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License: http://creativecommons.org/licenses/by/4.0/ (the “License”), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2014 Coelho et al 2014 Coelho et al</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c692t-b99f01b83fcf8da04b87c70bd21b1a2e6fac4d978bd1e41cb89e06cb5dc64d113</citedby><cites>FETCH-LOGICAL-c692t-b99f01b83fcf8da04b87c70bd21b1a2e6fac4d978bd1e41cb89e06cb5dc64d113</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938581/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3938581/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79343,79344</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24587185$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Lo, Anthony W. I.</contributor><creatorcontrib>Coelho, Ana L</creatorcontrib><creatorcontrib>Araújo, António</creatorcontrib><creatorcontrib>Gomes, Mónica</creatorcontrib><creatorcontrib>Catarino, Raquel</creatorcontrib><creatorcontrib>Marques, Agostinho</creatorcontrib><creatorcontrib>Medeiros, Rui</creatorcontrib><title>Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected]</title><title>PloS one</title><addtitle>PLoS One</addtitle><description>Non-small cell lung cancer (NSCLC) is the most common cancer and the leading cause of death from cancer worldwide. Antiangiogenic strategies directed towards tumor stroma are becoming gold standard in NSCLC treatment and researchers have been searching for biomarkers to identify patients for whom therapy with antiangiogenic inhibitors may be most beneficial and the importance of these as prognostic factors in NSCLC. The purpose of this study was to evaluate the prognostic value of circulating Ang-2 mRNA levels prior to treatment in NSCLC patients. The mRNA levels were determined by quantitative real-time PCR in the peripheral blood of 92 NSCLC patients. Our results demonstrate that patients with high circulating Ang-2 mRNA levels have diminished overall survival when compared to those with low mRNA levels (20.3 months vs 34.3 months, respectively; Log Rank Test, p = 0.016), when considering all NSCLC stages and this difference is even bigger when considering only patients with stage IV (15.9 months vs 31.3 months, respectively; Log Rank Test, p = 0.036). Moreover, circulating Ang-2 mRNA levels independently determine overall survival, and the concordance (c) index analysis showed that the definition of a nomogram that contains information regarding tumor stage, patients' smoking status and circulating Ang-2 mRNA levels present an increased capacity to predict overall survival in NSCLC patients (c-index 0.798). These results suggest that this nomogram could serve as a unique and practical tool to determine prognosis in NSCLC, not relying on the availability of adequate surgical or biopsy specimens of NSCLC. Attending to our results, the circulating Ang-2 mRNA levels should also be included in the design of preclinical studies and clinical trials involving antiangiogenic drugs targeting Ang-2, to guide adequate patient stratification and dose selection and increasing the likelihood of benefit to a level that is acceptable to patients and clinicians.</description><subject>Aged</subject><subject>Analysis</subject><subject>Angiogenesis</subject><subject>Angiopoietin-2 - blood</subject><subject>Angiopoietin-2 - genetics</subject><subject>Antiangiogenic agents</subject><subject>Antiangiogenics</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Biopsy</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - blood</subject><subject>Carcinoma, Non-Small-Cell Lung - diagnosis</subject><subject>Carcinoma, Non-Small-Cell Lung - genetics</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Drug delivery</subject><subject>Drug development</subject><subject>Drugs</subject><subject>Female</subject><subject>Gene Expression</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Kinases</subject><subject>Lung cancer</subject><subject>Lung diseases</subject><subject>Lung Neoplasms - blood</subject><subject>Lung Neoplasms - diagnosis</subject><subject>Lung Neoplasms - genetics</subject><subject>Lung Neoplasms - mortality</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical research</subject><subject>Medicine</subject><subject>Messenger RNA</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Neoplasm Staging</subject><subject>Nomograms</subject><subject>Non-small cell lung cancer</subject><subject>Non-small cell lung carcinoma</subject><subject>Oncology</subject><subject>Patients</subject><subject>Peripheral blood</subject><subject>Permeability</subject><subject>Predictive Value of Tests</subject><subject>Prognosis</subject><subject>RNA, Messenger - blood</subject><subject>RNA, Messenger - genetics</subject><subject>Smoking</subject><subject>Stroma</subject><subject>Surgery</subject><subject>Surgical instruments</subject><subject>Survival</subject><subject>Survival Analysis</subject><subject>Tumors</subject><subject>Vascular endothelial growth factor</subject><issn>1932-6203</issn><issn>1932-6203</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqNk1trFDEUxwdRbF39BqIBQfRh12SumT4Iy-JlYWmhVV9EQi4ns1OzkzXJ1PrtzXSnZVf6ICEkJL_zPzkn5yTJc4JnJKvIu0vbu46b2dZ2MMO4xnE-SI5JnaXTMsXZw739UfLE-0uMi4yW5ePkKM0LWhFaHCfrRetkb3houwbNu2aaos356RzB9daB963tkIErMP4EGWt_DhRfA1coWMRRB7_R1tmmsz60Emkug3VIx3l6sVgt0HdpnQMZQP14mjzS3Hh4Nq6T5OvHD18Wn6ers0_LxXw1lWWdhqmoa42JoJmWmiqOc0ErWWGhUiIIT6GMPnJVV1QoAjmRgtaASykKJctcEZJNkpc73a2xno1J8owUOEurFFMaieWOUJZfsq1rN9z9YZa37ObAuoZxF8MxwHQuJC6kEoLgvCZClJVOK51TDFjQKDlJ3o_eerEBJaELjpsD0cObrl2zxl6xrM5oQYfnvhkFnP3Vgw9s03oJxvAObH_z7pyU8cPLiL76B70_upFqeAyg7bSNfuUgyuZ5ReOoi0Frdg8Vh4JNK2NF6TaeHxi8PTCITIDr0PDee7a8OP9_9uzbIft6j42VZcLaW9OHWHn-EMx3oHTWewf6LskEs6EhbrPBhoZgY0NEsxf7H3RndNsB2V-FMQYi</recordid><startdate>20140228</startdate><enddate>20140228</enddate><creator>Coelho, Ana L</creator><creator>Araújo, António</creator><creator>Gomes, Mónica</creator><creator>Catarino, Raquel</creator><creator>Marques, Agostinho</creator><creator>Medeiros, Rui</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QO</scope><scope>7RV</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TG</scope><scope>7TM</scope><scope>7U9</scope><scope>7X2</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FG</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABJCF</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>ATCPS</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>D1I</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB.</scope><scope>KB0</scope><scope>KL.</scope><scope>L6V</scope><scope>LK8</scope><scope>M0K</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>M7S</scope><scope>NAPCQ</scope><scope>P5Z</scope><scope>P62</scope><scope>P64</scope><scope>PATMY</scope><scope>PDBOC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PTHSS</scope><scope>PYCSY</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope></search><sort><creationdate>20140228</creationdate><title>Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected]</title><author>Coelho, Ana L ; Araújo, António ; Gomes, Mónica ; Catarino, Raquel ; Marques, Agostinho ; Medeiros, Rui</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c692t-b99f01b83fcf8da04b87c70bd21b1a2e6fac4d978bd1e41cb89e06cb5dc64d113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Aged</topic><topic>Analysis</topic><topic>Angiogenesis</topic><topic>Angiopoietin-2 - blood</topic><topic>Angiopoietin-2 - genetics</topic><topic>Antiangiogenic agents</topic><topic>Antiangiogenics</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Biopsy</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - blood</topic><topic>Carcinoma, Non-Small-Cell Lung - diagnosis</topic><topic>Carcinoma, Non-Small-Cell Lung - genetics</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Drug delivery</topic><topic>Drug development</topic><topic>Drugs</topic><topic>Female</topic><topic>Gene Expression</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Kinases</topic><topic>Lung cancer</topic><topic>Lung diseases</topic><topic>Lung Neoplasms - blood</topic><topic>Lung Neoplasms - diagnosis</topic><topic>Lung Neoplasms - genetics</topic><topic>Lung Neoplasms - mortality</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical research</topic><topic>Medicine</topic><topic>Messenger RNA</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Neoplasm Staging</topic><topic>Nomograms</topic><topic>Non-small cell lung cancer</topic><topic>Non-small cell lung carcinoma</topic><topic>Oncology</topic><topic>Patients</topic><topic>Peripheral blood</topic><topic>Permeability</topic><topic>Predictive Value of Tests</topic><topic>Prognosis</topic><topic>RNA, Messenger - blood</topic><topic>RNA, Messenger - genetics</topic><topic>Smoking</topic><topic>Stroma</topic><topic>Surgery</topic><topic>Surgical instruments</topic><topic>Survival</topic><topic>Survival Analysis</topic><topic>Tumors</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Coelho, Ana L</creatorcontrib><creatorcontrib>Araújo, António</creatorcontrib><creatorcontrib>Gomes, Mónica</creatorcontrib><creatorcontrib>Catarino, Raquel</creatorcontrib><creatorcontrib>Marques, Agostinho</creatorcontrib><creatorcontrib>Medeiros, Rui</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Biotechnology Research Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Meteorological & Geoastrophysical Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Agricultural Science Collection</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Materials Science & Engineering Collection</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>Agricultural & Environmental Science Collection</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Materials Science Collection</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Materials Science Database</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Meteorological & Geoastrophysical Abstracts - Academic</collection><collection>ProQuest Engineering Collection</collection><collection>ProQuest Biological Science Collection</collection><collection>Agricultural Science Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Engineering Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Environmental Science Database</collection><collection>Materials Science Collection</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>Engineering Collection</collection><collection>Environmental Science Collection</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>TestCollectionTL3OpenAccess</collection><jtitle>PloS one</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Coelho, Ana L</au><au>Araújo, António</au><au>Gomes, Mónica</au><au>Catarino, Raquel</au><au>Marques, Agostinho</au><au>Medeiros, Rui</au><au>Lo, Anthony W. I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected]</atitle><jtitle>PloS one</jtitle><addtitle>PLoS One</addtitle><date>2014-02-28</date><risdate>2014</risdate><volume>9</volume><issue>2</issue><spage>e90009</spage><epage>e90009</epage><pages>e90009-e90009</pages><issn>1932-6203</issn><eissn>1932-6203</eissn><abstract>Non-small cell lung cancer (NSCLC) is the most common cancer and the leading cause of death from cancer worldwide. Antiangiogenic strategies directed towards tumor stroma are becoming gold standard in NSCLC treatment and researchers have been searching for biomarkers to identify patients for whom therapy with antiangiogenic inhibitors may be most beneficial and the importance of these as prognostic factors in NSCLC. The purpose of this study was to evaluate the prognostic value of circulating Ang-2 mRNA levels prior to treatment in NSCLC patients. The mRNA levels were determined by quantitative real-time PCR in the peripheral blood of 92 NSCLC patients. Our results demonstrate that patients with high circulating Ang-2 mRNA levels have diminished overall survival when compared to those with low mRNA levels (20.3 months vs 34.3 months, respectively; Log Rank Test, p = 0.016), when considering all NSCLC stages and this difference is even bigger when considering only patients with stage IV (15.9 months vs 31.3 months, respectively; Log Rank Test, p = 0.036). Moreover, circulating Ang-2 mRNA levels independently determine overall survival, and the concordance (c) index analysis showed that the definition of a nomogram that contains information regarding tumor stage, patients' smoking status and circulating Ang-2 mRNA levels present an increased capacity to predict overall survival in NSCLC patients (c-index 0.798). These results suggest that this nomogram could serve as a unique and practical tool to determine prognosis in NSCLC, not relying on the availability of adequate surgical or biopsy specimens of NSCLC. Attending to our results, the circulating Ang-2 mRNA levels should also be included in the design of preclinical studies and clinical trials involving antiangiogenic drugs targeting Ang-2, to guide adequate patient stratification and dose selection and increasing the likelihood of benefit to a level that is acceptable to patients and clinicians.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>24587185</pmid><doi>10.1371/journal.pone.0090009</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1932-6203 |
| ispartof | PloS one, 2014-02, Vol.9 (2), p.e90009-e90009 |
| issn | 1932-6203 1932-6203 |
| language | eng |
| recordid | cdi_plos_journals_1503272088 |
| source | MEDLINE; TestCollectionTL3OpenAccess; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Free Full-Text Journals in Chemistry; Public Library of Science (PLoS) |
| subjects | Aged Analysis Angiogenesis Angiopoietin-2 - blood Angiopoietin-2 - genetics Antiangiogenic agents Antiangiogenics Biomarkers Biomarkers, Tumor - blood Biomarkers, Tumor - genetics Biopsy Cancer Cancer therapies Carcinoma, Non-Small-Cell Lung - blood Carcinoma, Non-Small-Cell Lung - diagnosis Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Care and treatment Chemotherapy Clinical trials Drug delivery Drug development Drugs Female Gene Expression Health aspects Humans Kinases Lung cancer Lung diseases Lung Neoplasms - blood Lung Neoplasms - diagnosis Lung Neoplasms - genetics Lung Neoplasms - mortality Male Medical prognosis Medical research Medicine Messenger RNA Metastasis Middle Aged Neoplasm Staging Nomograms Non-small cell lung cancer Non-small cell lung carcinoma Oncology Patients Peripheral blood Permeability Predictive Value of Tests Prognosis RNA, Messenger - blood RNA, Messenger - genetics Smoking Stroma Surgery Surgical instruments Survival Survival Analysis Tumors Vascular endothelial growth factor |
| title | Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected] |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T00%3A03%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Circulating%20Ang-2%20mRNA%20expression%20levels:%20looking%20ahead%20to%20a%20new%20prognostic%20factor%20for%20NSCLC%20%5Bcorrected%5D&rft.jtitle=PloS%20one&rft.au=Coelho,%20Ana%20L&rft.date=2014-02-28&rft.volume=9&rft.issue=2&rft.spage=e90009&rft.epage=e90009&rft.pages=e90009-e90009&rft.issn=1932-6203&rft.eissn=1932-6203&rft_id=info:doi/10.1371/journal.pone.0090009&rft_dat=%3Cgale_plos_%3EA478787956%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1503272088&rft_id=info:pmid/24587185&rft_galeid=A478787956&rft_doaj_id=oai_doaj_org_article_f4bc05cdbb10491bb67f27f480e0b850&rfr_iscdi=true |